First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen

(2012) Norihiko Takahashi et al.   CANCER SCIENCE

MHC Class I-Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer

(2011) M. A. Morse et al.   CLINICAL CANCER RESEARCH

Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma

(2011) John A. Thompson et al.   JOURNAL OF IMMUNOTHERAPY

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

(2010) Matthias Wölfl et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers

(2010) G. Sinnathamby et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A Novel Breast/Ovarian Cancer Peptide Vaccine Platform That Promotes Specific Type-1 but not Treg/Tr1-type Responses

(2010) Mohan Karkada et al.   JOURNAL OF IMMUNOTHERAPY

Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity

(2009) J. R. Almeida et al.   BLOOD

Multipeptide vaccination in cancer patients

(2009) Lorenzo Pilla et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

(2009) Ravi A Madan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIVmac251 challenge

(2009) Elizabeth J. Faul et al.   VACCINE

TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer

(2008) N. B. Merchant et al.   CLINICAL CANCER RESEARCH

Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission

(2008) C. S.M. Diefenbach et al.   CLINICAL CANCER RESEARCH

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine

(2008) Jarrod P. Holmes et al.   JOURNAL OF CLINICAL ONCOLOGY

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

(2008) Jeffrey A. Sosman et al.   JOURNAL OF CLINICAL ONCOLOGY

A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer

(2008) Kimberly A. Chianese-Bullock et al.   JOURNAL OF IMMUNOTHERAPY

Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma

(2008) Miguel-Angel Perales et al.   MOLECULAR THERAPY